Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Omarigliptin in Type 2 Diabetes
NCT01217073Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2010
- Primary completion
- Jan 2012
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of omarigliptin in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Merck & Co. Primary endpoints: Change From Baseline in Plasma A1C Levels at 12 weeks, Percentage of Participants Who Experienced at Least One Adverse Event at 16 weeks and 3 more. Started Oct 2010; status: completed.
02
Drugs
omarigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01217073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01217073.